clonazepam has been researched along with Diabetic Neuropathies in 2 studies
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.
clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.
Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)
| Excerpt | Relevance | Reference |
|---|---|---|
| " For treating trigeminal neuralgia, carbamazepine had a combined number needed to treat of 2." | 6.17 | Anticonvulsant drugs for management of pain: a systematic review. ( Carroll, D; Jadad, AR; McQuay, H; Moore, A; Wiffen, P, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| McQuay, H | 1 |
| Carroll, D | 1 |
| Jadad, AR | 1 |
| Wiffen, P | 1 |
| Moore, A | 1 |
| Young, RJ | 1 |
| Clarke, BF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Erenumab as a Therapeutic Approach for the Management of Trigeminal Neuropathic Pain (TNP)[NCT05142228] | Phase 2 | 5 participants (Actual) | Interventional | 2022-04-01 | Terminated (stopped due to Low enrollment rate) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for clonazepam and Diabetic Neuropathies
| Article | Year |
|---|---|
Anticonvulsant drugs for management of pain: a systematic review.
Topics: Anticonvulsants; Carbamazepine; Clonazepam; Diabetic Neuropathies; Humans; Pain; Phenytoin; Treatmen | 1995 |
2 trials available for clonazepam and Diabetic Neuropathies
| Article | Year |
|---|---|
Anticonvulsant drugs for management of pain: a systematic review.
Topics: Anticonvulsants; Carbamazepine; Clonazepam; Diabetic Neuropathies; Humans; Pain; Phenytoin; Treatmen | 1995 |
Pain relief in diabetic neuropathy: the effectiveness of imipramine and related drugs.
Topics: Adult; Aged; Amitriptyline; Clinical Trials as Topic; Clonazepam; Diabetic Neuropathies; Double-Blin | 1985 |